Everolimus, an mTOR inhibitor, exhibits antitumor activity by disrupting various signaling pathways [27], and has been studied in combination with sorafenib in patients with unresectable or metastatic HCC [28]. Here, MTOR is linked to hepatocellular carcinoma.